Eli Lilly and (NYSE:LLY) Upgraded by UBS Group to Buy

UBS Group upgraded shares of Eli Lilly and (NYSE:LLYGet Rating) from a neutral rating to a buy rating in a research report released on Thursday, Marketbeat reports. The firm currently has $363.00 price objective on the stock, up from their prior price objective of $335.00.

Other equities research analysts also recently issued research reports about the stock. Morgan Stanley upped their target price on shares of Eli Lilly and from $395.00 to $412.00 and gave the company an overweight rating in a research note on Wednesday, September 7th. Citigroup increased their price objective on shares of Eli Lilly and from $285.00 to $370.00 in a research report on Thursday, August 25th. Barclays increased their price objective on shares of Eli Lilly and from $333.00 to $355.00 and gave the stock an overweight rating in a research report on Thursday, July 7th. JPMorgan Chase & Co. increased their price objective on shares of Eli Lilly and from $340.00 to $355.00 in a research report on Wednesday, June 1st. Finally, BMO Capital Markets increased their price objective on shares of Eli Lilly and from $369.00 to $396.00 and gave the stock an outperform rating in a research report on Tuesday, September 6th. Three equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Eli Lilly and currently has an average rating of Moderate Buy and a consensus price target of $332.19.

Eli Lilly and Trading Up 4.9 %

Shares of NYSE LLY opened at $310.87 on Thursday. Eli Lilly and has a fifty-two week low of $220.20 and a fifty-two week high of $335.33. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.10 and a quick ratio of 0.85. The firm has a market capitalization of $295.38 billion, a P/E ratio of 49.58, a P/E/G ratio of 1.95 and a beta of 0.38. The company’s 50 day simple moving average is $314.33 and its 200 day simple moving average is $304.45.

Eli Lilly and (NYSE:LLYGet Rating) last issued its earnings results on Thursday, August 4th. The company reported $1.25 EPS for the quarter, missing the consensus estimate of $1.86 by ($0.61). Eli Lilly and had a net margin of 19.58% and a return on equity of 85.58%. The firm had revenue of $6.49 billion during the quarter, compared to the consensus estimate of $6.85 billion. During the same period in the previous year, the company posted $1.87 EPS. The firm’s revenue for the quarter was down 3.7% on a year-over-year basis. On average, analysts predict that Eli Lilly and will post 7.97 EPS for the current year.

Eli Lilly and Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 9th. Stockholders of record on Monday, August 15th were given a $0.98 dividend. This represents a $3.92 dividend on an annualized basis and a dividend yield of 1.26%. The ex-dividend date was Friday, August 12th. Eli Lilly and’s dividend payout ratio (DPR) is presently 62.52%.

Insider Activity

In other news, Director Jackson P. Tai acquired 656 shares of the firm’s stock in a transaction dated Friday, August 12th. The stock was bought at an average price of $304.19 per share, with a total value of $199,548.64. Following the transaction, the director now directly owns 62,857 shares in the company, valued at approximately $19,120,470.83. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, Director Jackson P. Tai bought 656 shares of the business’s stock in a transaction dated Friday, August 12th. The stock was bought at an average price of $304.19 per share, for a total transaction of $199,548.64. Following the purchase, the director now owns 62,857 shares in the company, valued at approximately $19,120,470.83. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 89,458 shares of the firm’s stock in a transaction dated Thursday, July 28th. The stock was sold at an average price of $332.85, for a total transaction of $29,776,095.30. Following the sale, the insider now owns 103,875,441 shares of the company’s stock, valued at approximately $34,574,940,536.85. The disclosure for this sale can be found here. Insiders sold a total of 328,125 shares of company stock valued at $108,581,151 in the last quarter. Company insiders own 0.12% of the company’s stock.

Institutional Trading of Eli Lilly and

A number of hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in Eli Lilly and by 1.8% in the 1st quarter. Vanguard Group Inc. now owns 70,481,178 shares of the company’s stock worth $20,183,695,000 after purchasing an additional 1,219,424 shares in the last quarter. State Street Corp raised its stake in Eli Lilly and by 2.5% in the 4th quarter. State Street Corp now owns 33,929,864 shares of the company’s stock worth $9,372,107,000 after purchasing an additional 813,983 shares in the last quarter. FMR LLC raised its stake in Eli Lilly and by 2.9% in the 2nd quarter. FMR LLC now owns 32,439,666 shares of the company’s stock worth $10,517,913,000 after purchasing an additional 898,976 shares in the last quarter. Capital World Investors raised its stake in Eli Lilly and by 17.0% in the 1st quarter. Capital World Investors now owns 22,358,444 shares of the company’s stock worth $6,402,838,000 after purchasing an additional 3,242,548 shares in the last quarter. Finally, Jennison Associates LLC raised its stake in Eli Lilly and by 31.1% in the 2nd quarter. Jennison Associates LLC now owns 10,358,066 shares of the company’s stock worth $3,358,396,000 after purchasing an additional 2,456,760 shares in the last quarter. Institutional investors and hedge funds own 82.45% of the company’s stock.

Eli Lilly and Company Profile

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Articles

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.